Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy

Overview

Journal Case Rep Urol

Publisher Wiley

Specialty Urology

Date 2019 Apr 20

PMID 31001447

Citations 7

Authors

Abhishek Bhat

Bruno Nahar

Vivek Venkatramani

Indraneel Banerjee

Oleksandr N Kryvenko

Dipen J Parekh

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma, particularly the most common clear cell type, is one of the most aggressive of urological cancers with significant risk of metastatic spread. It also has a propensity for venotropism with a proportion of tumors developing thrombi up to the right atrium. The response with newly adopted targeted therapy has been considered to be in the evolutionary stage with no clear role with respect to debulking or reducing the size of the inferior vena cava (IVC) thrombus. We describe a case of a right-sided metastatic RCC with Level IV thrombus initially managed with Pazopanib followed by Nivolumab and Adalimumab followed by cytoreductive nephrectomy and IVC thrombectomy in the post-targeted therapy setting with complete curative response.

Citing Articles

Pathological Complete Response to Pembrolizumab plus Axitinib Combination following Serious Immune-Related Adverse Events in an Advanced Renal Cell Carcinoma Patient with a History of Rheumatoid Arthritis.

Bergamini M, Dalla Volta A, Valcamonico F, Caramella I, Buffoni M, Munari E Case Rep Oncol. 2024; 17(1):56-68.

PMID: 38188482 PMC: 10769506. DOI: 10.1159/000535460.

Decoding the multicellular ecosystem of vena caval tumor thrombus in clear cell renal cell carcinoma by single-cell RNA sequencing.

Shi Y, Zhang Q, Bi H, Lu M, Tan Y, Zou D Genome Biol. 2022; 23(1):87.

PMID: 35361264 PMC: 8969307. DOI: 10.1186/s13059-022-02651-9.

A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib.

Suzuki I, Kijima T, Takada-Owada A, Nakamura G, Uematsu T, Sakamoto K IJU Case Rep. 2021; 4(6):412-416.

PMID: 34755071 PMC: 8560442. DOI: 10.1002/iju5.12362.

Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports.

Tucker M, Beckermann K, Gordetsky J, Giannico G, Davis N, Rini B Front Oncol. 2021; 10:609235.

PMID: 33415079 PMC: 7783360. DOI: 10.3389/fonc.2020.609235.

Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.

Hagimoto H, Kashima S, Doi K, Nakayama S, Sano T, Imai S IJU Case Rep. 2020; 3(6):287-290.

PMID: 33163928 PMC: 7609183. DOI: 10.1002/iju5.12220.

References

Moch H, Gasser T, Amin M, Torhorst J, Sauter G, Mihatsch M . Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000; 89(3):604-14. View

Thomas A, Rini B, Lane B, Garcia J, Dreicer R, Klein E . Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2008; 181(2):518-23. DOI: 10.1016/j.juro.2008.10.001. View

Bex A, van der Veldt A, Blank C, van den Eertwegh A, Boven E, Horenblas S . Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol. 2009; 27(4):533-9. DOI: 10.1007/s00345-008-0368-7. View

Luo J, Zhou F, Xie D, Zhang Z, Liao B, Zhao H . Analysis of long-term survival in patients with localized renal cell carcinoma: laparoscopic versus open radical nephrectomy. World J Urol. 2009; 28(3):289-93. DOI: 10.1007/s00345-009-0487-9. View

Cowey C, Fielding J, Rathmell W . The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Urology. 2009; 75(5):1108-13.e1. DOI: 10.1016/j.urology.2009.06.105. View

Leibovich B, Lohse C, Crispen P, Boorjian S, Thompson R, Blute M . Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010; 183(4):1309-15. DOI: 10.1016/j.juro.2009.12.035. View

Hellenthal N, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding G . Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010; 184(3):859-64. PMC: 3105599. DOI: 10.1016/j.juro.2010.05.041. View

Cost N, Delacroix Jr S, Sleeper J, Smith P, Youssef R, Chapin B . The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011; 59(6):912-8. DOI: 10.1016/j.eururo.2011.02.032. View

Motzer R, Hutson T, Cella D, Reeves J, Hawkins R, Guo J . Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8):722-31. DOI: 10.1056/NEJMoa1303989. View

10.

Roquero L, Kryvenko O, Gupta N, Lee M . Characterization of Fibromuscular Pseudocapsule in Renal Cell Carcinoma. Int J Surg Pathol. 2015; 23(5):359-63. DOI: 10.1177/1066896915579198. View

11.

Choueiri T, Halabi S, Sanford B, Hahn O, Michaelson M, Walsh M . Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017; 35(6):591-597. PMC: 5455807. DOI: 10.1200/JCO.2016.70.7398. View

12.

Motzer R, Haas N, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E . Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017; 35(35):3916-3923. PMC: 6018511. DOI: 10.1200/JCO.2017.73.5324. View

13.

Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View

14.

Mejean A, Ravaud A, Thezenas S, Colas S, Beauval J, Bensalah K . Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018; 379(5):417-427. DOI: 10.1056/NEJMoa1803675. View